Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×First-generation antipsychotic, butyrophenone. Used as antiemetic.

Updated · Methodology

Mechanism

Droperidol prolongs the QT interval in a dose-dependent way. In a study of 40 surgical patients without known heart disease, median heart-rate-corrected QT rose by 37, 44 and 59 ms within 10 minutes of 0.1, 0.175 and 0.25 mg/kg (droperidol label, US Food and Drug Administration, FDA). Domperidone is also associated with QT prolongation. Epidemiological studies link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish droperidol SmPC lists domperidone among drugs that cause torsade de pointes through QT prolongation. The domperidone SmPC explains its contraindication of such combinations by a higher risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions (droperidol and domperidone SmPCs, AEMPS). Inhibitors of CYP1A2 and CYP3A4 slow the metabolism of droperidol, and CYP3A4 is the main enzyme that metabolises domperidone (droperidol and domperidone SmPCs, AEMPS). The documents, however, give no data on either drug changing the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With droperidol, QT prolongation, torsade de pointes, ventricular arrhythmias, cardiac arrest and sudden death have been reported, including at or below recommended doses and in people with no known risk factors (droperidol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and label, US Food and Drug Administration, FDA). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low potassium or magnesium and a slow heart rate (droperidol and domperidone SmPCs, AEMPS).

Management

The combination is contraindicated. The Spanish droperidol summary of product characteristics (SmPC) contraindicates droperidol in patients treated with QT-prolonging drugs and names domperidone among the drugs that must not be given at the same time. The Spanish domperidone SmPC contraindicates domperidone with QT-prolonging drugs (droperidol and domperidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US droperidol label also states that any drug that can prolong the QT interval should not be used with droperidol (droperidol label, US Food and Drug Administration, FDA). Droperidol is also contraindicated in known or suspected QT prolongation, that is, a heart-rate-corrected QT (QTc) above 450 ms in women and above 440 ms in men, in low potassium or magnesium and with a heart rate below 55 beats per minute (droperidol SmPC, AEMPS). In people at risk of arrhythmia, check electrolytes and creatinine and rule out QT prolongation before giving droperidol. If a risk of ventricular arrhythmia is suspected or known, keep pulse oximetry running continuously until 30 minutes after intravenous administration (droperidol SmPC, AEMPS). The US label requires a 12-lead electrocardiogram (ECG) in all patients before droperidol, and do not give droperidol if the QT interval is prolonged (droperidol label, FDA). Domperidone is contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease. Stop domperidone if signs of arrhythmia appear (domperidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Droperidol